Annals of Internal Medicine tip sheet for April 3, 2007

April 02, 2007

  1. New ACP Guideline for Mammography Screening Encourages Women 40 to 49 Years of Age to Become Part of the Decision-Making Process

    The American College of Physicians released a mammography screening guideline for women between ages 40 and 49 in the April 3, 2007, issue of Annals of Internal Medicine.

    The guideline says that according to the evidence studied, breast cancer risk is not evenly distributed in women between the ages of 40 and 49. Thus the benefits of screening mammography are not uniform in women in this age group. A decision that tries to balance the possible benefits and harms of screening mammography must therefore take into account one's risk of breast cancer and susceptibility to -- and concerns about -- the harms of screening.

    ACP does not say that women in this age group should not be screened for breast cancer. Nor does it say that all women should be screened. Rather, it says that women should discuss breast cancer screening with their primary care physician and make the decision that fits their risks and their preferences. A separate news release has been issued. (Guideline, p. 511, Background paper, p. 516, Patient summary, Editorial, p. 529.)

  2. Long-Term Effects of False-Positive Mammography Screening Not Clear

    In the same issue of Annals of Internal Medicine, authors reviewed 23 published studies of the long-term effects of false-positive mammography screening results on the behavior and feelings of women older than 40 (Review, p. 502).

    Authors found disparate results, e.g., in an American study, women with false-positive results were more likely to return for routine mammography screening; in a European study, false-positives had no effect on returning for routine mammography, and in a Canadian study, women with false-positive mammograms were less likely to return for routine screening. In general, women who received false-positives worried more about breast cancer than those with normal readings, but results suggest no long-term symptoms of depression.

  3. New Injected Drug Added to Traditional Drug May Help Type 2 Diabetes

    A study of 233 people with type 2 diabetes not well controlled with thiazolidinediones (with or without metformin) found that the addition of exenatide improved glycemic control better than a thiazolidinedione plus placebo (Article, p. 477).

    An editorial writer raised concerns about the study, such as studying patients not receiving maximal conventional therapy when the study began, not using lifestyle interventions to maximize diabetes control at baseline, and not providing information about subgroups prone to develop adverse drug reactions (Editorial p. 527).

  4. Study Finds Kidney Dialysis Outcomes Vary by Race and Region

    Using large national databases, researchers looked at demographics, medical data and data on dialysis treatment facility in ZIP codes of U.S. metropolitan cities with differing percentages of African-American residents (Article, p. 493). They found that the racial composition of the residential area is associated with the time to kidney transplantation for residents of the neighborhood, whether they are African-American or Caucasian. Moreover, the racial composition of the neighborhood was associated with the performance of the dialysis facility that serves residents of the neighborhood.
Embargoed for Release until 5 p.m. EDT, Monday, April 2, 2007

Note: Annals of Internal Medicine is published by the American College of Physicians. These highlights are not intended to substitute for articles as sources of information.

American College of Physicians

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to